WO1994011508A3 - Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods - Google Patents

Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods Download PDF

Info

Publication number
WO1994011508A3
WO1994011508A3 PCT/US1993/011316 US9311316W WO9411508A3 WO 1994011508 A3 WO1994011508 A3 WO 1994011508A3 US 9311316 W US9311316 W US 9311316W WO 9411508 A3 WO9411508 A3 WO 9411508A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
polypeptide
invention
hybrid
anti
cells
Prior art date
Application number
PCT/US1993/011316
Other languages
French (fr)
Other versions
WO1994011508A2 (en )
Original Assignee
Cancer Res Fund Of Contracosta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

A polypeptide consists of a variable region of the light or heavy chains of an antibody of a species selectively binding the human mammary fat globule (HMFG) antigen, and an antigen found on the surface or the cytoplasm of tumor cells such as carcinoma cells or that is released by the cells, combinations thereof operatively linked to one another, and mixtures thereof. The polypeptide may be glycosylated. A hybrid polypeptide comprises the polypeptide of the invention and an effector agent, and both polypeptides may be present as a composition with a non-proteolytic carrier as well as with a pharmaceutically acceptable carrier. Diagnostic kits comprises the polypeptide or hybrid polypeptide of the invention and other components such as anti-tumor antibody, and anti-constant region immunoglobulin, protein G or A, a solid support, and instructions for their use. Tumors may be imaged and/or diagnosed in vivo by administering the radiolabeled polypeptide of this invention and detecting any localized labeled polypeptide, and in vitro by contacting a biological sample with the hybrid polypeptide of the invention to form a complex with neoplastic antigen present in the sample, and detecting any complex formed. The growth or the size of a primary or metastasized tumor may be therapeutically inhibited or reduced by administering the polypeptide or hybrid polypeptide of the invention. A polynucleotide comprises an oligonucleotide encoding the polypeptide or hybrid polypeptide described above, hybrid vectors carry the polydeoxyribonucleotide(s) of the invention, and host cells are transfected with the hybrid vectors. Te polypeptide or hybrid polypeptide may be obtained by cloning one or more of the polydeoxyribonucleotide(s) of this invention. An anti-idiotype polypeptide comprises polyclonal antibodies raised against the polypeptide of this invention; monoclonal antibodies thereof; Fab, Fab', (Fab')2, and variable region fragments thereof; an oligopeptide comprising the amino acid sequence APDTRPA or tandem repeats thereof, combinations thereof and mixtures thereof. The hybrid polypeptide may also contain an effector agent and be provided as an anti-neoplastic vaccine in a vaccination kit. The serum concentration of a circulating polypeptide that binds to an antigen present on the surface or in the cytoplasm of tumor cells or that are released by the cells may be lowered by administering the anti-idiotype polypeptide of the invention to accelerate the clearance of the polypeptide.
PCT/US1993/011316 1992-11-13 1993-11-15 Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods WO1994011508A3 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US97770692 true 1992-11-13 1992-11-13
US97770792 true 1992-11-13 1992-11-13
US07/977,706 1992-11-13
US07/977,707 1992-11-13
US12801593 true 1993-09-28 1993-09-28
US08/128,015 1993-09-28

Publications (2)

Publication Number Publication Date
WO1994011508A2 true WO1994011508A2 (en) 1994-05-26
WO1994011508A3 true true WO1994011508A3 (en) 1994-07-07

Family

ID=27383656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/011316 WO1994011508A3 (en) 1992-11-13 1993-11-15 Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods

Country Status (1)

Country Link
WO (1) WO1994011508A3 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041801B1 (en) 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
WO2001012217A9 (en) * 1999-08-18 2002-06-27 Altarex Inc Therapeutic antibody against muc-1 antigen and methods for their use
US6716966B1 (en) 1999-08-18 2004-04-06 Altarex Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
GB0007343D0 (en) * 2000-03-28 2000-05-17 Antisoma Res Ltd Compounds for targeting
US9265811B2 (en) 2006-02-09 2016-02-23 Alba Therapeutics Corporation Formulations for a tight junction effector
US20090069247A1 (en) 2006-10-06 2009-03-12 Blake Paterson Use of tight junction antagonists to treat inflammatory bowel disease

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002945A1 (en) * 1984-11-09 1986-05-22 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
WO1990005142A1 (en) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
WO1990012319A1 (en) * 1989-04-05 1990-10-18 John Muir Cancer & Aging Institute Monoclonal antibody recognizing a glycoprotein of human milk-fat globule membrane mucin antigen
WO1992004380A1 (en) * 1990-09-07 1992-03-19 Unilever Plc Specific binding agents
WO1992007939A2 (en) * 1990-11-01 1992-05-14 John Muir Cancer & Research Institute Polypeptide with 46kd hmfg differentiation antigen binding specificity
EP0534742A1 (en) * 1991-09-26 1993-03-31 Celltech Therapeutics Limited Anti-human milk fat globule humanised antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986002945A1 (en) * 1984-11-09 1986-05-22 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
WO1990005142A1 (en) * 1988-11-10 1990-05-17 Imperial Cancer Research Technology Ltd. Polypeptides
WO1990012319A1 (en) * 1989-04-05 1990-10-18 John Muir Cancer & Aging Institute Monoclonal antibody recognizing a glycoprotein of human milk-fat globule membrane mucin antigen
WO1992004380A1 (en) * 1990-09-07 1992-03-19 Unilever Plc Specific binding agents
WO1992007939A2 (en) * 1990-11-01 1992-05-14 John Muir Cancer & Research Institute Polypeptide with 46kd hmfg differentiation antigen binding specificity
EP0534742A1 (en) * 1991-09-26 1993-03-31 Celltech Therapeutics Limited Anti-human milk fat globule humanised antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. DIENHART ET AL.: "Imaging of non-small cell lung cancers with a monoclonal antibody, KC-4G3, which recognizes a human milk fat globule antigen.", CANCER RESEARCH, vol. 50, no. 21, 1 November 1990 (1990-11-01), PHILADELPHIA PA, USA, pages 7068 - 7076 *
E. BLANK ET AL.: "A novel anti-breast epithelial mucin Mab (BrE-3). Characterization and experimental biodistribution and immunotherapy.", CANCER JOURNAL, vol. 5, no. 1, 1992, VILLEJUIF, FRANCE, pages 38 - 44 *
J. COUTO ET AL.: "Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.", HYBRIDOMA, vol. 12, no. 1, February 1993 (1993-02-01), NEW YORK, USA, pages 15 - 23 *
S. STARK ET AL.: "Antibodies that are specific for a single amino acid interchange in a protein epitope use structurally distinct variable regions.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, 1991, NEW YORK, USA, pages 613 - 624 *

Also Published As

Publication number Publication date Type
WO1994011508A2 (en) 1994-05-26 application

Similar Documents

Publication Publication Date Title
Sandberg et al. Purification and partial characterization of a soluble elastin-like protein from copper-deficient procine aorta
Ishizaka et al. Reversed type allergic skin reactions by anti-γE-globulin antibodies in humans and monkeys
Whitlow et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability
Slamon et al. Studies of the human c-myb gene and its product in human acute leukemias
Brekken et al. Vascular endothelial growth factor as a marker of tumor endothelium
Marchalonis et al. Isolation and partial characterization of lymphocyte surface immunoglobulins
Reardan et al. Antibodies against metal chelates
Pagnah Zoli et al. Purification and characterization of a bovine pregnancy-associated glycoprotein
Herlyn et al. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody
US4762706A (en) Peptide antibodies and their use in detecting oncogene products
Natali et al. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40 S to human melanoma cells
Ceriani et al. Circulating human mammary epithelial antigens in breast cancer
US4514505A (en) Monoclonal antibody mixtures and use thereof for enhanced sensitivity immunoassays
US4873313A (en) Specific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigens
Flanders et al. Antibodies to peptide determinants in transforming growth factor. beta. and their applications
Colcher et al. Radioimmunolocalization of human carcinoma xenografts with B72. 3 second generation monoclonal antibodies
EP0586002A2 (en) Monoclonal antibodies recognizing the epidermal growth factor receptor, cells and methods for their production and compositions containing them
Tourville et al. The human female reproductive tract: Immunohistological localization of γA, γG, γM, secretory “piece,” and lactoferrin
US20040005647A1 (en) Anti-MUC-1 single chain antibodies for tumor targeting
US5869620A (en) Multivalent antigen-binding proteins
US6872393B2 (en) Polyalkylene oxide-modified single chain polypeptides
US5591430A (en) Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
Ortmann et al. Synthetic peptides anchor T cell-specific TNP epitopes to MHC antigens.
Primus et al. Localization of GW-39 human tumors in hamsters by affinity-purified antibody to carcinoembryonic antigen
US4810781A (en) Methods of preparing epitopes of tumor associated antigens

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA